

Special Issue

Unraveling SARS-CoV-2 Pathogenesis: Development of Vaccines and Therapeutics for COVID-19

Message from the Guest Editor

Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. Currently, the world is concerned about the SARS-CoV-2, the causative agent of COVID-19, which was initially identified in the city of Wuhan, China in December 2019. Tens of thousands of cases and several thousand deaths have been reported in many countries. SARS-CoV-2 is highly contagious based on the number of infected cases to date. There is a need for development of vaccines and effective therapeutics that can control the current outbreak. We are interested in manuscripts that focus on replication, viral life cycle, and pathogenesis of SARS-CoV-2. We are also interested in areas of identification of novel drug targets and the development of vaccines and therapeutics for COVID-19. We aim to publish a variety of manuscripts that represent different research studies that investigate unique aspects of viral pathogenesis and life cycle and identify/test different vaccines and antivirals for efficacy against SARS-CoV-2.

Guest Editor

Dr. Hatem A. Elshabrawy

Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Conroe, TX 77304, USA

Deadline for manuscript submissions

closed (31 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/45099

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).